{"entity":{"id":"atx-295","kind":"drug","name":"ATX-295","aka":[],"tldr":"ATX-295 is an experimental oral small molecule from Accent Therapeutics, in phase 1 trials for high-grade serous ovarian cancer, squamous non-small cell lung cancer and advanced or metastatic solid tumours.","summary":"ATX-295 is an oral small molecule from Accent Therapeutics. An inhibitor of KIF18A, a motor protein needed for cell division in tumours with chromosomal instability; the company says aneuploid cancer cells die quickly while cells with normal chromosome numbers are spared. Its furthest stage is phase 1, for high-grade serous ovarian cancer (including platinum-resistant), squamous non-small cell lung cancer and advanced or metastatic solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT06799065 recruiting; Accent retains full worldwide rights. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Accent Therapeutics: accenttx.com","url":"https://accenttx.com/approach-pipeline/"},{"label":"Accent Therapeutics: accenttx.com","url":"https://accenttx.com/approach-pipeline/"},{"label":"Accent Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06799065"},{"label":"ClinicalTrials.gov: trials of ATX-295","url":"https://clinicaltrials.gov/search?intr=ATX-295"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","nsclc","metastatic-cancer"],"sections":[],"technologies":[],"targets":["kif18a"],"drugs":[],"companies":["accent-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06799065"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ATX-295","modality":"Oral small molecule","mechanism":"An inhibitor of KIF18A, a motor protein needed for cell division in tumours with chromosomal instability; the company says aneuploid cancer cells die quickly while cells with normal chromosome numbers are spared.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/atx-295/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"kif18a","kind":"target","name":"KIF18A","route":"/targets/kif18a/"}],"company":[{"id":"accent-therapeutics","kind":"company","name":"Accent Therapeutics","route":"/companies/accent-therapeutics/"}],"trial":[{"id":"nct06799065","kind":"trial","name":"First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer","route":"/trials/nct06799065/"}]}}